ANIP News and Press, ANI Pharmaceuticals Inc. From 08/30/22

ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24 th Annual Global Investment Conference as fo...

The U.S. Food and Drug Administration (FDA) approved ANI Pharmaceuticals' ( NASDAQ: ANIP ) generic dexamethasone tablets USP 1.5mg, 4mg and 6mg. The company's dexamethasone tablets are the generic version of reference drug Decadron. Dexamethasone is a type of ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Dexamethasone Tablets USP 1.5mg, 4mg and 6mg. ANI’s Dexamethasone Table...

ANI Pharmaceuticals, Inc. (ANIP) Q2 2022 Earnings Conference Call August 8, 2022 08:00 ET Company Participants Lisa Wilson - Investor Relations Nikhil Lalwani - President & Chief Executive Officer Steve Carey - Chief Financial Officer, Senior Vice President o...

ANI Pharma ( NASDAQ: ANIP ) is trading 2.5% higher after the company reported better-than-expected Q2 revenue and 2022 guidance that was in-line with estimates., helped by higher sales of purified cortrophin Gel and generic pharmaceuticals. The company reite...

ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q2 Non-GAAP EPS of $0.13 misses by $0.09 . Revenue of $73.9M (+52.0% Y/Y) beats by $1.93M . Adjusted non-GAAP EBITDA of $9.9M. Full-Year 2022 Guidance : Reiterates total company net revenue guidan...

Second Quarter 2022 Results: -- Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) – -- Lead Rare Disease asset, Purified Cortrophin ® Gel (Repository Cortic...

ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is $0.22 (-67.2% Y/Y) and the consensus Revenue Estimate is $71.97M (+48.0% Y/Y). Over the last 2 years, ANIP has b...

ANIP , APRN , ASRT , BNTX , CLVS , D , DCTH , DTIL , ELAN , ENR , FREY , GOLD , HE , HEP , ITUB , KNDI , KOS , LINC , OTCPK:LKNCY , OSG , PDSB , PLTR , PRTY , RDWR , RETA , SOHU , TGN...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Acebutolol Hydrochloride Capsules. ANI’s Acebutolol Hydrochloride Capsules are the generic version of the Reference Listed Drug (RLD) Sectral ® ...